Download Publications for Nikolas Haass Publications for Nikolas Haass 2016

Publications for Nikolas Haass
Publications for Nikolas Haass
2016
Beaumont, K., Hill, D., Daignault, S., Lui, G.,
Sharp, D., Gabrielli, B., Weninger, W., Haass, N.
(2016). Cell cycle phase-specific drug resistance
as an escape mechanism of melanoma cells. The
Journal of Investigative Dermatology, 136(7),
1479-1489. <a
href="http://dx.doi.org/10.1016/j.jid.2016.02.805
">[More Information]</a>
Haass, N. (2016). Die Rolle der dynamischen
Tumorheterogenitat. Spectrum Dermatologie,
2016 (3), 14-17.
Skalamera, D., Dahmer-Heath, M., Stevenson,
A., Pinto, C., Shah, E., Daignault, S., Said, N.,
Davis, M., Haass, N., et al (2016). Genome-wide
gain-of-function screen for genes that induce
epithelial-to-mesenchymal transition in breast
cancer. Oncotarget, 7(38), 61000-61020. <a
href="http://dx.doi.org/10.18632/oncotarget.113
14">[More Information]</a>
Vaidyanathan, S., Cato, K., Tang, L., Pavey, S.,
Haass, N., Gabrielli, B., Duijf, P. (2016). In vivo
overexpression of Emi1 promotes chromosome
instability and tumorigenesis. Oncogene, 35(41),
5446-5455. <a
href="http://dx.doi.org/10.1038/onc.2016.94">[
More Information]</a>
Haass, N. (2016). JNK-ERK signalling in
melanoma: rewired or entangled? British Journal
of Dermatology, 175(6), 1139-1140. <a
href="http://dx.doi.org/10.1111/bjd.14903">[Mo
re Information]</a>
Giles, K., Brown, R., Ganda, C., Podgorny, M.,
Candy, P., Wintle, L., Richardson, K.,
Kalinowski, F., Stuart, L., Epis, M., Haass, N., et
al (2016). microRNA-7-5p inhibits melanoma
cell proliferation and metastasis by suppressing
RelA/NF-(kappa)B. Oncotarget, 7(22),
31663-31680. <a
href="http://dx.doi.org/10.18632/oncotarget.942
1">[More Information]</a>
Maadi, H., Moshtaghian, A., Taha, M., Mowla,
S., Kazeroonian, A., Haass, N., Javeri, A. (2016).
Multimodal tumor suppression by miR-302
cluster in melanoma and colon cancer. The
International Journal of Biochemistry and Cell
Biology, 81, 121-132. <a
href="http://dx.doi.org/10.1016/j.biocel.2016.11.
004">[More Information]</a>
2015
Ravindran Menon, D., Das, S., Krepler, C.,
Vultur, A., Rinner, B., Schauer, S., Kashofer, K.,
Wagner, K., Zhang, G., Bonyadi Rad, E., et al
(2015). A stress-induced early innate response
causes multidrug tolerance in melanoma.
Oncogene, 34(34), 4448-4459. <a
href="http://dx.doi.org/10.1038/onc.2014.372">[
More Information]</a>
Spoerri, L., Oo, Z., Larsen, J., Haass, N.,
Gabrielli, B., Pavey, S. (2015). Cell Cycle
Checkpoint and DNA Damage Response Defects
as Anticancer Targets: From Molecular
Mechanisms to Therapeutic Opportunities. In
Georg T. Wondrak (Eds.), Stress Response
Pathways in Cancer: From Molecular Targets to
Novel Therapeutics, (pp. 29-49). Dordrecht:
Springer Science+Business Media.
Haass, N. (2015). Dynamic tumor heterogeneity
in melanoma therapy: how do we address this in
a novel model system? Melanoma Management,
2(2), 93-95.
Burke, M., Morais, C., Oliver, K., Lambie, D.,
Gobe, G., Carroll, R., Staatz, C., Sinnya, S.,
Soyer, P., Winterford, C., et al (2015).
Expression of Bcl-xL and Mcl-1 in the
Nonmelanoma
Skin Cancers of Renal Transplant Recipients.
American Journal of Clinical Pathology, 143(4),
514-526. <a
href="http://dx.doi.org/10.1309/AJCPQNB5WA
3PLQBK">[More Information]</a>
Tikoo, S., Haass, N. (2015). Friends or foes:
IL-10 and TGF-β in melanoma. Experimental
Dermatology, 24(4), 254-255. <a
href="http://dx.doi.org/10.1111/exd.12661">[Mo
re Information]</a>
Beaumont, K., Anfosso, A., Ahmed, F.,
Weninger, W., Haass, N. (2015). Imaging- and
Flow Cytometry-based Analysis of Cell Position
and the Cell Cycle in 3D Melanoma Spheroids.
Journal of Visualized Experiments: JOVE,
28(106), 1-9. <a
href="http://dx.doi.org/10.3791/53486">[More
Information]</a>
Tonnessen, C., Haass, N. (2015). Melanoma:
From Tumor-Specific Mutations to a New
Molecular Taxonomy and Innovative
Therapeutics. In Thomas Bieber, Frank Nestle
(Eds.), Personalized Treatment Options in
Dermatology, (pp. 7-27). Berlin:
Springer-Verlag.
Ke, Y., Hummel, A., Stevens, C., Gladbach, A.,
Ippati, S., Bi, M., Lee, W., Halliday, G., Haass,
N., Kiernan, M., et al (2015). Short-term
suppression of A315T mutant human TDP-43
expression improves functional deficits in a
novel inducible transgenic mouse model of
FTLD-TDP and ALS. Acta Neuropathologica,
130(5), 661-678. <a
href="http://dx.doi.org/10.1007/s00401-015-148
6-0">[More Information]</a>
Haass, N., Nassif, N., McGowan, E. (2015).
Publications for Nikolas Haass
Switching the sphingolipid rheostat in the
treatment of diabetes and cancer comorbidity
from a problem to an advantage. BioMed
Research International, 2015, 1-9. <a
href="http://dx.doi.org/10.1155/2015/165105">[
More Information]</a>
2014
Moloney, F., Guitera, P., Coates, E., Haass, N.,
Ho, K., Khoury, R., O'Connell, R., Raudonikis,
L., Schmid, H., Mann, G., Menzies, S. (2014).
Detection of Primary Melanoma in Individuals at
Extreme High Risk: A Prospective 5-year
Follow-up Study. JAMA Dermatology, 150(8),
819-827. <a
href="http://dx.doi.org/10.1001/jamadermatol.20
14.514">[More Information]</a>
Hill, D., Lovat, P., Haass, N. (2014). Induction
of endoplasmic reticulum stress as a strategy for
melanoma therapy:is there a future? Melanoma
Management, 1(2), 127-137. <a
href="http://dx.doi.org/10.2217/MMT.14.16">[
More Information]</a>
Haass, N., Schumacher, U. (2014). Melanoma
never says die. Experimental Dermatology,
23(7), 471-472. <a
href="http://dx.doi.org/10.1111/exd.12400">[Mo
re Information]</a>
Beaumont, K., Kumaran - Mohana, N., Haass, N.
(2014). Modeling Melanoma In Vitro and In
Vivo. Healthcare, 2, 27-46. <a
href="http://dx.doi.org/10.3390/healthcare20100
27">[More Information]</a>
Haass, N., Beaumont, K., Hill, D., Anfosso, A.,
Mrass, P., Munoz, M., Kinjyo, I., Weninger, W.
(2014). Real-time cell cycle imaging during
melanoma growth, invasion and drug response.
Pigment Cell & Melanoma Research, 27(5),
764-776. <a
href="http://dx.doi.org/10.1111/pcmr.12274">[
More Information]</a>
Wang, K., Beaumont, K., Otte, N., Font Sadurni,
J., Bailey, C., van Geldermalsen, M., Sharp, D.,
Tiffen, J., Ryan, R., Jormakka, M., Haass, N.,
Rasko, J., Holst, J. (2014). Targeting glutamine
transport to suppress melanoma cell growth.
International Journal of Cancer, 135(5),
1060-1071. <a
href="http://dx.doi.org/10.1002/ijc.28749">[Mor
e Information]</a>
Mohana-Kumaran, N., Hill, D., Allen, D., Haass,
N. (2014). Targeting the intrinsic apoptosis
pathway as a strategy for melanoma therapy.
Pigment Cell & Melanoma Research, 27(4),
525-539. <a
href="http://dx.doi.org/10.1111/pcmr.12242">[
More Information]</a>
Haass, N. (2014). The Petrel 2014: Annual
Report for Southport The Brisbane Seabird Study
Group SOSSA, Northern Sector | The
Grey-headed Albatross conundrum at the
Australian east coast, (pp. 96 - 107). Brisbane,
QLD, Australia: SOSSA.
2013
Stehn, J., Haass, N., Bonello, T., Desouza, M.,
Kottyan, G., Treutlein, H., Zeng, J., Nascimento,
P., Sequeira, V., Butler, T., Allanson, M.,
Winlaw, D., Reeve, V., Weninger, W., et al
(2013). A Novel Class of Anticancer Compounds
Targets the Actin Cytoskeleton in Tumor Cells.
Cancer Research, 73(16), 5169-5182. <a
href="http://dx.doi.org/10.1158/0008-5472.CAN
-12-4501">[More Information]</a>
Tong, P., Qin, J., Cooper, C., Lowe, P., Murrell,
D., Kossard, S., Ng, L., Roediger, B., Weninger,
W., Haass, N. (2013). A quantitative approach to
histopathological dissection of elastin-related
disorders using multiphoton microscopy. British
Journal of Dermatology, 169(4), 869-879. <a
href="http://dx.doi.org/10.1111/bjd.12430">[Mo
re Information]</a>
Pavey, S., Spoerri, L., Haass, N., Gabrielli, B.
(2013). DNA repair and cell cycle checkpoint
defects as drivers and therapeutic targets in
melanoma. Pigment Cell & Melanoma Research,
26(6), 805-816. <a
href="http://dx.doi.org/10.1111/pcmr.12136">[
More Information]</a>
Brandner, J., Haass, N. (2013). Melanoma's
connections to the tumour microenvironment.
Pathology, 45(5), 443-452. <a
href="http://dx.doi.org/10.1097/PAT.0b013e328
363b3bd">[More Information]</a>
Wroblewski, D., Mijatov, B., Mohana-Kumara,
N., Lai, F., Gallagher, S., Haass, N., Zhang, X.,
Hersey, P. (2013). The BH3-mimetic ABT-737
sensitizes human melanoma cells to apoptosis
induced by
selective BRAF inhibitors but does not reverse
acquired resistance. Carcinogenesis, 34(2),
237-247. <a
href="http://dx.doi.org/10.1093/carcin/bgs330">[
More Information]</a>
2012
Smalley, K., Aplin, A., Flaherty, K., Hoeller, C.,
Bosserhoff, A., Haass, N., Bosenberg, M., Ribas,
A., Barnhill, R., Kudchadkar, R., et al (2012).
Meeting report from the 2011 International
Melanoma Congress, Tampa, Florida. Pigment
Cell & Melanoma Research, 25(1), E1-E11. <a
href="http://dx.doi.org/10.1111/j.1755-148X.201
1.00943.x">[More Information]</a>
Coates, E., Moloney, F., Guitera, P., Haass, N.,
Ho, K., Khoury, R., Mann, G., Menzies, S.
Publications for Nikolas Haass
(2012). Melanoma detection in high risk patients:
a case series. 20th Regional Conference of
Dermatology 2012.
Lucas, K., Kumaran - Mohana, N., Lau, D.,
Zhang, X., Hersey, P., Huang, D., Weninger, W.,
Haass, N., Allen, J. (2012). Modulation of
NOXA and MCL-1 as a Strategy for Sensitizing
Melanoma Cells to the BH3-Mimetic ABT-737.
Clinical Cancer Research, 18(3), 783-795. <a
href="http://dx.doi.org/10.1158/1078-0432.CCR11-1166">[More Information]</a>
Moloney, F., Guitera, P., Coates, E., Haass, N.,
Ho, K., Khoury, R., Mann, G., Menzies, S.
(2012). Observation of a five year high risk
clinic for primary melanoma. 3rd World
Congress of Dermoscopy, Australia.
2011
Kuphal, S., Haass, N. (2011). Cell-Cell and
Cell-Matrix Contacts in Melanoma and the
Tumor Microenvironment. In Anja Bosserhoff
(Eds.), Melanoma Development: Molecular
Biology, Genetics and Clinical Application, (pp.
181-215). Vienna: Springer.
McGowan, E., Alling, N., Jackson, E., Yagoub,
D., Haass, N., Allen, J., Martinello-Wilks, R.
(2011). Evaluation of Cell Cycle Arrest in
Estrogen Responsive MCF-7 Breast Cancer
Cells: Pitfalls of the MTS Assay. PloS One, 6(6),
1-8. <a
href="http://dx.doi.org/10.1371/journal.pone.002
0623">[More Information]</a>
Hersey, P., Smalley, K., Weeraratna, A.,
Bosenberg, M., Zhang, X., Haass, N., Paton, E.,
Mann, G., Scolyer, R. (2011). Meeting report
from the 7th International Melanoma Congress,
Sydney, November, 2010. Pigment Cell &
Melanoma Research, 24(1), e1-e15. <a
href="http://dx.doi.org/10.1111/j.1755-148X.201
0.00811.x">[More Information]</a>
2010
de Zwaan, S., Haass, N. (2010). Genetics of
basal cell carcinoma. Australasian Journal of
Dermatology, 51(2), 81-92; quiz 93-4. <a
href="http://dx.doi.org/10.1111/j.1440-0960.200
9.00579.x">[More Information]</a>
Haass, N., Ripperger, D., Wladykowski, E.,
Dawson, P., Gimotty, P., Blome, C., Fischer, F.,
Schmage, P., Moll, I., Brandner, J. (2010).
Melanoma progression exhibits a significant
impact on connexin expression patterns in the
epidermal tumor microenvironment.
Histochemistry and Cell Biology, 133(1),
113-124. <a
href="http://dx.doi.org/10.1007/s00418-009-065
4-5">[More Information]</a>
Cocciolone, R., Crotty, K., Andrews, L., Haass,
N., Moloney, F. (2010). Multiple Desmoplastic
Melanomas in Birt-Hogg-Dube Syndrome and a
Proposed Signaling Link Between Folliculin, the
mTOR Pathway, and Melanoma Susceptibility.
Archives of Dermatology, 146(11), 1316-1318.
<a
href="http://dx.doi.org/10.1001/archdermatol.20
10.333">[More Information]</a>
Lee, J., Li, L., Brafford, P., van den Eijnden, M.,
Halloran, M., Sproesser, K., Haass, N., Smalley,
K., Tsai, J., Bollag, G., et al (2010). PLX4032, a
potent inhibitor of the B-Raf V600E oncogene,
selectively inhibits V600E-positive melanomas.
Pigment Cell & Melanoma Research, 23(6),
820-827. <a
href="http://dx.doi.org/10.1111/j.1755-148X.201
0.00763.x">[More Information]</a>
2009
Santiago-Walker, A., Li, L., Haass, N., Herlyn,
M. (2009). Melanocytes: from morphology to
application. Skin Pharmacology and Physiology,
22(2), 114-121. <a
href="http://dx.doi.org/10.1159/000178870">[M
ore Information]</a>
Haass, N., Smalley, K. (2009). Melanoma
biomarkers: current status and utility in
diagnosis, prognosis, and response to therapy.
Molecular Diagnosis and Therapy, 13(5),
283-296. <a
href="http://dx.doi.org/10.2165/11317270-00000
0000-00000">[More Information]</a>
2008
Tsai, J., Lee, J., Wang, W., Zhang, J., Cho, H.,
Mamo, S., Bremer, R., Gillette, S., Kong, J.,
Haass, N., et al (2008). Discovery of a selective
inhibitor of oncogenic B-Raf kinase with potent
antimelanoma activity. Proceedings of the
National Academy of Sciences of the United
States of America (PNAS), 105(8), 3041-3046.
<a
href="http://dx.doi.org/10.1073/pnas.071174110
5">[More Information]</a>
Haass, N. (2008). From xiphophorus to
melanoma-a tribute to steven kazianis
(1966-2008). Zebrafish, 5(2), 91-92. <a
href="http://dx.doi.org/10.1089/zeb.2008.9992">
[More Information]</a>
Smalley, K., Lioni, M., Noma, K., Haass, N.,
Herlyn, M. (2008). In vitro three-dimensional
tumor microenvironment models for anticancer
drug discovery. Expert Opinion on Drug
Discovery, 3(1), 1-10. <a
href="http://dx.doi.org/10.1517/17460441.3.1.1"
>[More Information]</a>
Haass, N., Hoeller, C., Herlyn, M. (2008).
Targeting Signaling Pathways - in the search of
Melanoma's Achilles' heel. In Menashe Bar-Eli
Publications for Nikolas Haass
(Eds.), Regulation of Gene Expression in the
Tumor Environment, (pp. 27-42). United States:
Springer.
Haass, N., Sproesser, K., Nguyen, T., Contractor,
R., Medina, C., Nathanson, K., Herlyn, M.,
Smalley, K. (2008). The mitogen-activated
protein/extracellular signal-regulated kinase
kinase inhibitor AZD6244 (ARRY-142886)
induces growth arrest in melanoma cells and
tumor regression when combined with docetaxel.
Clinical Cancer Research, 14(1), 230-239. <a
href="http://dx.doi.org/10.1158/1078-0432.CCR07-1440">[More Information]</a>
2007
Smalley, K., Contractor, R., Haass, N., Kulp, A.,
Atilla-Gokcumen, G., Williams, D., Bregman,
H., Flaherty, K., Soengas, M., Meggers, E., et al
(2007). An organometallic protein kinase
inhibitor pharmacologically activates p53 and
induces apoptosis in human melanoma cells.
Cancer Research, 67(1), 209-217. <a
href="http://dx.doi.org/10.1158/0008-5472.CAN
-06-1538">[More Information]</a>
Wenke, A., Kjellman, C., Lundgren-Akerlund,
E., Uhlmann, C., Haass, N., Herlyn, M.,
Bosserhoff, A. (2007). Expression of integrin
alpha10 is induced in malignant melanoma.
Cellular Oncology, 29(5), 373-386. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=17726260">[More Information]</a>
Smalley, K., Contractor, R., Haass, N., Lee, J.,
Nathanson, K., Medina, C., Flaherty, K., Herlyn,
M. (2007). Ki67 expression levels are a better
marker of reduced melanoma growth following
MEK inhibitor treatment than phospho-ERK
levels. British Journal of Cancer, 96(3),
445-449. <a
href="http://dx.doi.org/10.1038/sj.bjc.6603596">
[More Information]</a>
2006
Haass, N., Wladykowski, E., Kief, S., Moll, I.,
Brandner, J. (2006). Differential induction of
connexins 26 and 30 in skin tumors and their
adjacent epidermis. Journal of Histochemistry
and Cytochemistry: imaging the spectrum of cell
biology, 54(2), 171-182. <a
href="http://dx.doi.org/10.1369/jhc.5A6719.2005
">[More Information]</a>
Smalley, K., Haass, N., Brafford, P., Lioni, M.,
Flaherty, K., Herlyn, M. (2006). Multiple
signaling pathways must be targeted to overcome
drug resistance in cell lines derived from
melanoma metastases. Molecular Cancer
Therapeutics, 5(5), 1136-1144. <a
href="http://dx.doi.org/10.1158/1535-7163.MCT
-06-0084">[More Information]</a>
2005
Haass, N., Smalley, K., Li, L., Herlyn, M.
(2005). Adhesion, migration and communication
in melanocytes and melanoma. Pigment Cell
Research, 18(3), 150-159. <a
href="http://dx.doi.org/10.1111/j.1600-0749.200
5.00235.x">[More Information]</a>
Haass, N., Herlyn, M. (2005). Normal human
melanocyte homeostasis as a paradigm for
understanding melanoma. The journal of
investigative dermatology. Symposium
proceedings, 10(2), 153-163. <a
href="http://dx.doi.org/10.1111/j.1087-0024.200
5.200407.x">[More Information]</a>
Smalley, K., Brafford, P., Haass, N., Brandner,
J., Brown, E., Herlyn, M. (2005). Up-regulated
expression of zonula occludens protein-1 in
human melanoma associates with N-cadherin
and contributes to invasion and adhesion. The
American Journal of Pathology, 166(5),
1541-1554. <a
href="http://www.ncbi.nlm.nih.gov/entrez/query.
fcgi?cmd=Retrieve&db=pubmed&dopt=Abstract
&list_uids=15855653">[More Information]</a>